Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Current Evidence on the Relationship Between Two Polymorphisms in the NBS1 Gene and Breast Cancer Risk: a Meta-analysis

  • Zhang, Zhi-Hua (Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University) ;
  • Yang, Lin-Sheng (Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University) ;
  • Huang, Fen (Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University) ;
  • Hao, Jia-Hu (Department of Maternal and Child Health, School of Public Health, Anhui Medical University) ;
  • Su, Pu-Yu (Department of Maternal and Child Health, School of Public Health, Anhui Medical University) ;
  • Sun, Ye-Huan (Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University)
  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Introduction: Published studies on the association between Nijmegen breakage syndrome 1(NBS1) gene polymorphisms and breast cancer risk have been inconclusive, and a meta-analysis was therefore performed for clarification. Methods: Eligible articles were identified by a search of MEDLINE and EMBASE bibliographic databases for the period up to March 2012. The presence of between-study heterogeneity was investigated using the chi-square-based Cochran's Q statistic test. When there was statistical heterogeneity, the random effects model was chosen; otherwise, fixed effects estimates were reported as an alternative approach. Results: A total of 11 eligible articles (14 case-control studies) were identified, nine case-control studies were for the 657del5 mutation (7,534 breast cancer cases, 14,034 controls) and five case-control studies were for the I171V mutation (3,273 breast cancer cases, 4,004 controls). Our analysis results indicated that the 657del5 mutation was associated with breast cancer risk (carriers vs. non-carriers: pooled OR =2.63, 95% CI: 1.76-3.93), whereas the I171V mutation was not (carriers vs. non-carriers: pooled OR =1.52, 95% CI: 0.70-3.28). Conclusion: The present meta-analysis suggests that the 657del5 gene mutation in the NBS1 gene plays a role in breast cancer risk, while the I171V mutation does not exert a significant influence.

Keywords

References

  1. Bogdanova N, Feshchenko S, Schurmann P, et al (2008a). Nijmegen Breakage Syndrome mutations and risk of breast cancer. Int J Cancer, 122, 802-6. https://doi.org/10.1002/ijc.23168
  2. Bogdanova N, Schurmann P, Waltes R, et al (2008b). NBS1 variant I171V and breast cancer risk. Breast Cancer Res Treat, 112, 75-9. https://doi.org/10.1007/s10549-007-9820-4
  3. Buslov KG, Iyevleva AG, Chekmariova EV, et al (2005). NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia. Int J Cancer, 114, 585-9. https://doi.org/10.1002/ijc.20765
  4. Carlomagno F, Chang-Claude J, Dunning AM, et al (1999). Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer. Genes Chromosomes Cancer, 25, 393-5. https://doi.org/10.1002/(SICI)1098-2264(199908)25:4<393::AID-GCC12>3.0.CO;2-8
  5. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  6. Desjardins S, Beauparlant JC, Labrie Y, et al (2009). Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer. BMC Cancer, 9, 181. https://doi.org/10.1186/1471-2407-9-181
  7. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  8. Gorski B, Cybulski C, Huzarski T, et al (2005). Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat, 92, 19-24. https://doi.org/10.1007/s10549-005-1409-1
  9. Gorski B, Debniak T, Masojc B, et al (2003). Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer, 106, 379-81. https://doi.org/10.1002/ijc.11231
  10. Kanka C, Brozek I, Skalska B, et al (2007). Germline NBS1 mutations in families with aggregation of Breast and/or ovarian cancer from north-east Poland. Anticancer Res, 27, 3015-8.
  11. Lau J, Ioannidis JP, and Schmid CH (1997). Quantitative synthesis in systematic reviews. Ann Intern Med, 127, 820-6. https://doi.org/10.7326/0003-4819-127-9-199711010-00008
  12. Mantel N, and Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  13. Mosor M, Ziolkowska I, Pernak-Schwarz M, et al (2006). Association of the heterozygous germline I171V mutation of the NBS1 gene with childhood acute lymphoblastic leukemia. Leukemia, 20, 1454-6. https://doi.org/10.1038/sj.leu.2404285
  14. Nowak J, Mosor M, Ziolkowska I, et al (2008). Heterozygous carriers of the I171V mutation of the NBS1 gene have a significantly increased risk of solid malignant tumours. Eur J Cancer, 44, 627-30. https://doi.org/10.1016/j.ejca.2008.01.006
  15. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  16. Pharoah PD, Dunning AM, Ponder BA, et al (2004). Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer, 4, 850-60. https://doi.org/10.1038/nrc1476
  17. Roznowski K, Januszkiewicz-Lewandowska D, Mosor M, et al (2008). I171V germline mutation in the NBS1 gene significantly increases risk of breast cancer. Breast Cancer Res Treat, 110, 343-8. https://doi.org/10.1007/s10549-007-9734-1
  18. Steffen J, Nowakowska D, Niwinska A, et al (2006). Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer, 119, 472-5. https://doi.org/10.1002/ijc.21853
  19. Steffen J, Varon R, Mosor M, et al (2004). Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int J Cancer, 111, 67-71. https://doi.org/10.1002/ijc.20239
  20. Varon R, Seemanova E, Chrzanowska K, et al (2000). Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations. Eur J Hum Genet, 8, 900-902. https://doi.org/10.1038/sj.ejhg.5200554
  21. Ziolkowska I, Mosor M, Wierzbicka M, et al (2007). Increased risk of larynx cancer in heterozygous carriers of the I171V mutation of the NBS1 gene. Cancer Sci, 98, 1701-5. https://doi.org/10.1111/j.1349-7006.2007.00594.x

Cited by

  1. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBNcontribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study vol.16, pp.3, 2014, https://doi.org/10.1186/bcr3669
  2. Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment vol.32, pp.19, 2014, https://doi.org/10.1200/JCO.2013.53.6607
  3. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer vol.15, pp.11, 2015, https://doi.org/10.1586/14737140.2015.1090879
  4. Estimating cumulative risks for breast cancer for carriers of variants in uncommon genes vol.15, pp.3, 2016, https://doi.org/10.1007/s10689-016-9896-2
  5. Growing recognition of the role for rare missense substitutions in breast cancer susceptibility vol.8, pp.4, 2014, https://doi.org/10.2217/bmm.13.143
  6. A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations vol.27, pp.5, 2018, https://doi.org/10.1007/s10897-018-0238-4